An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir

• DOI: 10.14218/jcth.2022.00091
• Publication Date: 2022-06-06T13:55:41Z
• Authors: Yi-Qi Liu; Chi Zhang; Jia-Wen Li; Li-Hua Cao; Zhan-Qing Zhang; Wei-Feng Zhao; Qing-Hua Shang; Da-Zhi Zhang; An-Lin Ma; Qing Xie; Hong-Lian Gui; Guo Zhang; Ying-Xia Liu; Jia Shang; Shi-Bin Xie; Jun Li; Xu-Qing Zhang; Zhi-Qiang Zou; Yu-Ping Chen; Zong Zhang; Ming-Xiang Zhang; Jun Cheng; Fu-Chun Zhang; Li-Hua Huang; Jia-Bin Li; Qing-Hua Meng; Hai-Bin Yu; Yu-Qiang Mi; Yan-Zhong Peng; Zhi-Jin Wang; Li-Ming Chen; Fan-Ping Meng; Wan-Hua Ren; Lang Bai; Yi-Lan Zeng; Rong Fan; Xian-Zhi Lou; Wei-Feng Liang; Hui Liu; Hui Zhuang; Hong Zhao; Gui-Qiang Wang
• Keywords: Entecavir; Hepatitis B; Liver Cancer

Chronic hepatitis B (CHB) can cause liver fibrosis and lead to cirrhosis cancer. As the effectiveness of antiviral therapy reverse is limited, We aimed evaluate effect An-Luo-Hua-Xian pill (ALHX) on regression in CHB patients treated with entecavir (ETV).Treatment-naïve were randomly ETV alone or combined ALHX (ETV+ALHX) between October 1, 2013 December 31, 2020. Demographic, laboratory, histology data before after 78 weeks treatment collected. The Ishak score (F) was used required a decrease F ≥1 treatment.A total 780 enrolled, 394 second biopsy included per-protocol population, 132 group 262 ETV+ALHX group. After treatment, rate significantly higher than that at baseline F≥3 patients: 124/211 (58.8%) vs. 45/98 (45.9%), p=0.035. percentage decreased stiffness measurement (LSM) group: 156/211 (73.9%) 62/98 (63.%), p=0.056. Logistic analysis showed associated [odds ratio (OR)=1.94, p=0.018], family history hepatocellular carcinoma contrary. (OR=0.41, p=0.031).ETV increased patients.